CN112955430A - 一种布瓦西坦及其中间体的制备方法 - Google Patents

一种布瓦西坦及其中间体的制备方法 Download PDF

Info

Publication number
CN112955430A
CN112955430A CN201980070829.XA CN201980070829A CN112955430A CN 112955430 A CN112955430 A CN 112955430A CN 201980070829 A CN201980070829 A CN 201980070829A CN 112955430 A CN112955430 A CN 112955430A
Authority
CN
China
Prior art keywords
brivaracetam
compound shown
solvent
compound
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980070829.XA
Other languages
English (en)
Other versions
CN112955430B (zh
Inventor
樊海生
占轶鹏
尹凯
季翔
刘丰豪
石凯强
郭效文
黄鲁宁
陶安平
顾虹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Kesheng Pharmaceutical Research And Development Co ltd
Zhejiang Huahai Pharmaceutical Co Ltd
Original Assignee
Shanghai Kesheng Pharmaceutical Research And Development Co ltd
Zhejiang Huahai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Kesheng Pharmaceutical Research And Development Co ltd, Zhejiang Huahai Pharmaceutical Co Ltd filed Critical Shanghai Kesheng Pharmaceutical Research And Development Co ltd
Publication of CN112955430A publication Critical patent/CN112955430A/zh
Application granted granted Critical
Publication of CN112955430B publication Critical patent/CN112955430B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本申请涉及一种布瓦西坦中间体的制备方法(I)，包括如下步骤：将B‑P所示化合物和1S,2S‑二苯基乙二胺溶于拆分溶剂中，析晶，过滤，重结晶，得B‑Q所示化合物，再转化为B‑R所示的布瓦西坦中间体；该方法可以有效地拆分B‑P所示化合物。本申请还提供了利用B‑R所示的化合物制备布瓦西坦的方法；该方法在制备过程中不需要采用手性色谱柱分离异构体，仅进行萃取，洗涤，干燥，浓缩等简单步骤即可分离有效成分，分离过程简单，大大降低了布瓦西坦生产成本。
Figure DDA0003039544050000011

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201980070829.XA 2018-12-19 2019-12-12 一种布瓦西坦及其中间体的制备方法 Active CN112955430B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811558017.3A CN111333563B (zh) 2018-12-19 2018-12-19 一种布瓦西坦中间体的制备方法
CN2018115580173 2018-12-19
PCT/CN2019/124801 WO2020125536A1 (zh) 2018-12-19 2019-12-12 一种布瓦西坦及其中间体的制备方法

Publications (2)

Publication Number Publication Date
CN112955430A true CN112955430A (zh) 2021-06-11
CN112955430B CN112955430B (zh) 2023-03-07

Family

ID=71100396

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811558017.3A Active CN111333563B (zh) 2018-12-19 2018-12-19 一种布瓦西坦中间体的制备方法
CN201980070829.XA Active CN112955430B (zh) 2018-12-19 2019-12-12 一种布瓦西坦及其中间体的制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811558017.3A Active CN111333563B (zh) 2018-12-19 2018-12-19 一种布瓦西坦中间体的制备方法

Country Status (4)

Country Link
US (1) US20220048856A1 (zh)
EP (1) EP3901137B1 (zh)
CN (2) CN111333563B (zh)
WO (1) WO2020125536A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113651745A (zh) * 2021-09-09 2021-11-16 上海医药工业研究院 布瓦西坦中间体及其制备方法和纯化方法
CN115028563A (zh) * 2022-07-15 2022-09-09 苏州诚和医药化学有限公司 一种布瓦西坦中间体的制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942516A (zh) * 2019-03-27 2019-06-28 成都克莱蒙医药科技有限公司 化合物ra在制备布瓦西坦中间体手性丁内酯中的用途
CN115806519A (zh) * 2022-12-22 2023-03-17 浙江普洛家园药业有限公司 一种布瓦西坦中间体的拆分方法及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004182670A (ja) * 2002-12-05 2004-07-02 Toray Ind Inc 光学活性１−保護インドリン−２−カルボン酸誘導体の製造方法および光学活性インドリン−２−カルボン酸誘導体の製造方法
CN106748950A (zh) * 2017-01-13 2017-05-31 成都美域高制药有限公司 一种布瓦西坦及其中间体的制备方法
CN107513031A (zh) * 2016-06-16 2017-12-26 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
CN108101823A (zh) * 2018-02-13 2018-06-01 扬州奥锐特药业有限公司 一种高手性纯度内酰胺中间体及布瓦西坦的制备方法
CN108101824A (zh) * 2018-02-13 2018-06-01 扬州奥锐特药业有限公司 一种高手性纯度内酰胺中间体及布瓦西坦的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028435A1 (en) * 2003-09-24 2005-03-31 Ucb, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives
EP1773802A1 (en) * 2004-07-23 2007-04-18 Pharmacia & Upjohn Company LLC Enantioselective method for separing substituted 2-trifluoromethyl-2h-chromene-3-carboxylic acid derivatives
WO2007065634A1 (en) * 2005-12-07 2007-06-14 Ucb Pharma, S.A. 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses
US8338621B2 (en) * 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
HRP20211518T1 (hr) * 2015-11-03 2021-12-24 UCB Biopharma SRL Postupak priprave brivaracetama
WO2018042393A1 (en) * 2016-09-05 2018-03-08 Micro Labs Limited Novel process for the preparation of brivaracetam

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004182670A (ja) * 2002-12-05 2004-07-02 Toray Ind Inc 光学活性１−保護インドリン−２−カルボン酸誘導体の製造方法および光学活性インドリン−２−カルボン酸誘導体の製造方法
CN107513031A (zh) * 2016-06-16 2017-12-26 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
CN106748950A (zh) * 2017-01-13 2017-05-31 成都美域高制药有限公司 一种布瓦西坦及其中间体的制备方法
CN108101823A (zh) * 2018-02-13 2018-06-01 扬州奥锐特药业有限公司 一种高手性纯度内酰胺中间体及布瓦西坦的制备方法
CN108101824A (zh) * 2018-02-13 2018-06-01 扬州奥锐特药业有限公司 一种高手性纯度内酰胺中间体及布瓦西坦的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEO A.PAQUETTE著: "(S,S)-1,2-二苯基乙二胺", 《不对称合成中的手性试剂》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113651745A (zh) * 2021-09-09 2021-11-16 上海医药工业研究院 布瓦西坦中间体及其制备方法和纯化方法
CN115028563A (zh) * 2022-07-15 2022-09-09 苏州诚和医药化学有限公司 一种布瓦西坦中间体的制备方法
CN115028563B (zh) * 2022-07-15 2024-04-09 苏州诚和医药化学有限公司 一种布瓦西坦中间体的制备方法

Also Published As

Publication number Publication date
WO2020125536A1 (zh) 2020-06-25
CN111333563A (zh) 2020-06-26
CN112955430B (zh) 2023-03-07
CN111333563B (zh) 2023-11-07
US20220048856A1 (en) 2022-02-17
EP3901137B1 (en) 2023-01-25
EP3901137A1 (en) 2021-10-27
EP3901137A4 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
CN112955430B (zh) 一种布瓦西坦及其中间体的制备方法
SG177205A1 (en) Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of nep inhibitors
CN110615744B (zh) 一种布瓦西坦中间体及其制备方法
CN102875537A (zh) 一种新的抗血栓药物的制备方法
EP2327708A2 (en) Purification method for adefovir dipivoxil
WO2018233562A1 (zh) 一种奥司他韦及其异构体的制备方法
CN102060723A (zh) 氨基酸阳离子脂质体纳米颗粒的制备方法
CN105130999A (zh) 一种西格列汀杂质的合成方法
CN102786494A (zh) 利托那韦异构体杂质的合成研究及控制方法
CN113024434A (zh) 一种布瓦西坦中间体的制备方法
CN110015978B (zh) O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
EP4144724A1 (en) Brivaracetam and method for preparing intermediate thereof
CN108602758B (zh) 制备反式-4-氨基-1-环己烷基羧酸及其衍生物的方法
CN113582902A (zh) 布瓦西坦及其中间体的制备方法
CN105646284A (zh) 一种拉科酰胺的合成方法
CN101279929B (zh) 一种光学活性的3-氨基-n-环丙基-2-羟基己酰胺的制备方法
CN106928040A (zh) Sglt2抑制剂中间体的制备方法
CN107793342A (zh) 一种布瓦西坦的制备方法
CN113121413B (zh) 一种jak3酶抑制剂关键中间体的制备方法
CN107501155A (zh) 一种抗病毒药物中间体的制备方法
CN110790708B (zh) 一种艾利西平中间体的制备方法
JP2617329B2 (ja) 光学活性なアミノアルコールの製造法
JPH01311060A (ja) ３，４‐ジヒドロキシ‐２‐ピロリジノン誘導体およびそれらの製造法
CN113943240A (zh) 一种布瓦西坦的新制备方法
CN115819269A (zh) 一种拉考沙胺碱降解杂质及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Fan Haisheng

Inventor after: An Jianguo

Inventor after: Gu Hong

Inventor after: Zhan Yipeng

Inventor after: Yin Kai

Inventor after: Ji Xiang

Inventor after: Liu Fenghao

Inventor after: Shi Kaiqiang

Inventor after: Guo Xiaowen

Inventor after: Huang Luning

Inventor after: Tao Anping

Inventor before: Fan Haisheng

Inventor before: Gu Hong

Inventor before: Zhan Yipeng

Inventor before: Yin Kai

Inventor before: Ji Xiang

Inventor before: Liu Fenghao

Inventor before: Shi Kaiqiang

Inventor before: Guo Xiaowen

Inventor before: Huang Luning

Inventor before: Tao Anping

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant